Board of Directors
Mr. Berkowitz is one of the rare executives whose career has spanned most key verticals in global healthcare with executive committee and other senior roles at UnitedHealth Group, Walgreens Boots Alliance and Merck. Prior to Real Endpoints, Jeff served as an Executive Vice President of UnitedHealth Group/Optum where he lead Optum’s International division as CEO while also driving key strategic initiatives within Optum’s pharmacy benefits management division. Prior to joining UnitedHealth Group/Optum in 2016, Jeff served at the Walgreens Boots Alliance, Inc. as President of Pharma and Global Market Access. Berkowitz serves on the board of directors of Lundbeck, Esperion Therapeutics, Zealand Pharmaceuticals and the drug distributor, Uniphar. Berkowitz also served on the Board of Directors of the Swiss-American Chamber of Commerce.
Jonathan Jonas oversees JVC Investment Partners’ alternative investment portfolio targeting direct private equity, growth equity and venture capital investments. Jonathan has over twenty years of business experience in the healthcare and financial services industries. His background in finance and operations has resulted in significant growth in JVC’s assets under management. Prior to joining JVC, Jonathan held various positions of increasing leadership and responsibility at Boston Scientific Corporation, working in finance, sales and operations, including overseeing sales operations in Boston Scientific’s Cardiac Rhythm Management Division. Jonathan serves on the Board of Directors of Trisol Medical Ltd and on the Board of Trustees of the University of Chicago Medical Center. Jonathan is a registered CPA in the State of Illinois. He holds a BA in Economics from the University of Michigan, a General Course Degree from the London School of Economics and an MBA from Northwestern University Kellogg School of Management.
Dr. Yuval Cabilly is a Co-Founder and Managing Partner of Israel Biotech Fund. Dr. Cabilly has vast experience in identifying, funding and engaging in business development activities of Israeli biotech companies. Dr. Cabilly received his PhD in molecular cell biology from Tel Aviv University, where he focused his research on a neurodegenerative disease, and several of his articles have been published in well-known scientific journals.
Mr. Kronfeld is the Chairman of JK&B Capital, L.L.C., a venture capital firm, which he founded in 1995. Prior thereto he served as a General Partner at Boston Capital Ventures, the Vice President of Acquisitions and Venture Investments at Ameritech, a Senior Manager at Booz Allen & Hamilton and a Systems Analyst at Electronic Data Systems. Since February 2010, Mr. Kronfeld has been a director, and a member of the compensation committee, of Dynasil Corporation of America (NASDAQ-GM:DYSL). Mr.Kronfeld holds MS in Computer Science from Stevens Institute of Technology and MBA from Wharton Business School.
Mr. Mogle is the VP Corporate Development of Mapi Pharma and has over 15 years of executive experience in the life science and chemical industries. From 2003 until 2012, Mr. Mogle served in several capacities, including company secretary, investor relations director and as the head of the supply chain of Makhteshim Agan Industries Ltd. (currently ADAMA), and was responsible for sales planning and inventory management which is valued at over $1 billion. Prior to Makhteshim Agan Industries Ltd., Mr. Mogle served as business development manager of the digital video division of Nice Systems Ltd., and as an economist in the Israeli Ministry of Finance. Mr. Mogle has a B.A., with honors, in economics and an MBA, majoring in finance and accounting, both from the Hebrew University of Jerusalem, Israel.
Dr. Itamar Borowitz is General Partner in Crossroad VC, the high-tech investment arm of the Generali Insurance Group in Israel and also served as General Partner in the China-Israel Innovation Center Fund (Shenzhen). Dr. Borowitz was the CEO of the Phoenix Insurance Group, and served as the Chairman of the Israeli Insurance Association. Dr. Borowitz is a member of the Board of Governors of the of Tel Aviv University and member of the Board of Governors of the Hebrew University in Jerusalem, where he serves as a member of the Executive Committee and the Endowments and the Investment Committees of the university. Dr. Borowitz is the Chairman of Yissum, the Technology Transfer Company of The Hebrew University in Jerusalem. Dr. Borowitz holds a PhD in Physics, an MBA, and a B.A. in General History from Tel Aviv University, and a B.Sc. and M.Sc. in Mathematics and Physics from the Hebrew University in Jerusalem.
Mr. Marom is a founder of Pharma Two B and serves on its board since it was incorporated. In addition, Mr. Marom is Chairman & CEO of Mapi Pharma and Stem Cell Medicine. He brings vast experience in management, operations, business and strategic planning in the pharmaceutical industry, where he held the positions over the years. Past positions include VP of Operations at Teva Pharmaceuticals’ API and Innovative divisions; COO of Peptor Ltd; CEO of Gamida Cell (NASDAQ: GMDA) a leader in hematopoietic (blood) stem cell therapeutics; President and CEO of Makhteshim Chemical Works Ltd., followed by position of SVP of Supply Chain at Makhteshim-Agan Group (ADAMA ChemChina). Mr. Marom holds B.Sc. with distinction in Chemical Engineering from the Technion – Israel Institute of Technology.